Art

J-GLOBAL ID：202002223317062606   Reference number：20A2742423

一気にやって来た!産婦人科におけるゲノム医療時代 産婦人科における遺伝性乳がん卵巣がん症候群(HBOC)診療

Author (2)： KOBAYASHI YUSUKE (慶応大 医 産婦人科学) ,  AOKI DAISUKE (慶応大 医 産婦人科学)
Material： Hormone Frontier in Gynecology  (ホルモンフロンティアインジャイネコロジー)
Volume： 27  Issue： 4  Page： 251-255  Publication year： Dec. 01, 2020 
JST Material Number： L3856A  ISSN： 1340-220X  Document type： Article
Article type： 文献レビュー  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： PARP inhibitor ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A2742423&from=J-GLOBAL&jstjournalNo=L3856A") }}

JST classification (2)： Tumors(=neoplasms)of female genitalia and fetus  (GS04000K) ,  Treatment for tumors in general  (GE03031L)

Substance index (1)： Olaparib

Reference (13)：

• Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017 ; 317: 2402-16.
• Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers : a meta-analysis. Eur J Cancer. 2010 ; 46 : 2275-84.
• Rebbeck TR, Kauff ND, Domchek SM, et al. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009 ; 101 : 80-7.
• Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 ; 304 : 967-75.
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1. 2020. (accessed : 2020-10-14)

Terms in the title (4)： 産婦人科 ,  ゲノム医療 ,  遺伝性乳がん卵巣がん症候群 ,  診療